C94.32
Mast cell leukemia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Mast cell leukemia (ICL) is an extremely rare and aggressive type of blood cancer characterized by the rapid proliferation of abnormal mast cells within the bone marrow and blood. Mast cells are a type of white blood cell involved in allergic responses and immune system regulation. When these cells multiply uncontrollably, they can interfere with normal blood cell production and cause widespread symptoms. The condition is classified under ICD-10 code C94.32 when it is diagnosed in a state of relapse, meaning the disease has returned after initial treatment.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting mast cell growth regulation Predisposing genetic syndromes or hereditary conditions Environmental factors that may trigger abnormal immune responses Unknown factors in many cases, as is common with rare cancers
Key Symptoms: Unexplained fatigue and weakness Unintentional weight loss Fever and night sweats Skin reactions such as flushing, bursting out in redness, or hives Abdominal discomfort or pain Frequent infections Bleeding or easy bruising Swelling or enlarged lymph nodes Bone pain or fragility Difficulty breathing or chest tightness
Diagnostic & Treatment
Diagnosis Path: Blood tests: Complete blood count (CBC) showing abnormal counts, and serum tryptase levels which are often elevated in mast cell disorders Bone marrow biopsy: Examining marrow samples for abnormal mast cell infiltration Molecular testing: Detecting genetic mutations or markers associated with mast cell proliferation Imaging studies: CT scans or PET scans to assess organ involvement or lymphadenopathy Microscopic examination: Identifying abnormal mast cells with specific staining techniques
Treatment Protocols: Chemotherapy: Using drugs to control and reduce abnormal cell proliferation Targeted therapies: Medications aimed at specific genetic mutations or pathways involved in mast cell growth Immunotherapy: Enhancing the immune system's ability to fight malignant cells Supportive care: Managing symptoms such as allergic reactions, pain, or anemia Stem cell transplantation: In select cases, using bone marrow transplants to replace diseased marrow with healthy cells Clinical trials: Participating in research studies investigating new therapies
Clinical Advice & FAQs
Billing Guidance
Is C94.32 a billable ICD-10 code?
Yes, C94.32 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C94.32?
Clinical documentation must specify the nature of Mast cell leukemia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference